Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

MSLN-CAR-T cell therapy

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Shanghai Yihao Biotech

Drug class:

Mesothelin-targeted CAR-T immunotherapy

Related drugs:

‹

›

MSLN positive	Lung Non-Small Cell Squamous Cancer	MSLN positive	Lung Non-Small Cell Squamous Cancer	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D
MSLN positive	Mesothelioma	MSLN positive	Mesothelioma	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D
MSLN positive	Pancreatic Cancer	MSLN positive	Pancreatic Cancer	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D